19.00USD+1.01%Mkt Cap: 1.61B USDP/E: —Last update: 2026-05-26
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutical…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap1.61B USD
Enterprise Value967.82M USD
Revenue (TTM)42.95M USD
Gross Profit-102.46M USD
Net Income (TTM)-38.63M USD
Revenue/Share0.4910 USD
Last Price19.00 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees187
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-10.40
PEG—
EV/EBITDA-6.92
EV/Revenue22.53
P/S37.13
P/B3.05
EPS (TTM)-1.48
EPS (Forward)-1.81
52W Range
3.90069% of range25.77
52W High25.77 USD
52W Low3.900 USD
Profitability
Gross Margin-238.54%
Oper. Margin-1188.46%
EBITDA Margin0.00%
Profit Margin-31.23%
ROE-16.57%
ROA-8.61%
Growth
Revenue Growth-95.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-22.80M USD
CapEx (TTM)4.70M USD
FCF Margin-179.64%
FCF Yield-4.80%
Net Debt-627.16M USD
Net Debt/EBITDA4.48
Balance Sheet
Debt/Equity0.17
Current Ratio9.54
Quick Ratio9.44
Book Value/Sh6.190 USD
Cash/Share7.886 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)32.33 USD
Target Range29.00 USD – 37.00 USD
# Analysts6
Ownership
Shares Out.84.48M
Float52.98M
Insiders0.59%
Institutions113.05%
Short Interest
Short Ratio15.8d
Short % Float18.23%
Short % Out.17.95%
Shares Short15.14M
Short (prev mo.)13.40M
Technical
SMA 5017.93 (+6.0%)
SMA 20014.56 (+30.5%)
Beta1.62
S&P 52W Chg28.31%
Avg Vol (30d)781.26K
Avg Vol (10d)726.20K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—